Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 562

Results For "US"

8099 News Found

BridgeBio Pharma, Sentynl Therapeutics receive marketing authorization in the EU for fosdenopterin
Drug Approval | September 22, 2022

BridgeBio Pharma, Sentynl Therapeutics receive marketing authorization in the EU for fosdenopterin

NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.


Aster Pharmacy forays into Bangladesh
Healthcare | September 22, 2022

Aster Pharmacy forays into Bangladesh

Aster Pharmacy will be operated by GD Assist Limited in Bangladesh.


Reasons for the surge in M& A in healthcare and pharmaceutical sectors in India: Ankit Poddar & Navroz Mahudawala, Candle Partners
Opinion | September 22, 2022

Reasons for the surge in M& A in healthcare and pharmaceutical sectors in India: Ankit Poddar & Navroz Mahudawala, Candle Partners

Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.


Shilpa Medicare receives tentative approval for Tenofovir Alafenamide Tablets
Drug Approval | September 22, 2022

Shilpa Medicare receives tentative approval for Tenofovir Alafenamide Tablets

The ANDA was filed as 'First to File' submission on NCE-1 date.


Azelis expands pharmaceutical offerings with Clariant
News | September 21, 2022

Azelis expands pharmaceutical offerings with Clariant

Azelis’ customers now have access to products including the well-established Polyglykol portfolio, as well as a brand-new range of Motusflex and VitiPure excipients.


NATCO gets CTPR launch approval from Delhi High Court
News | September 21, 2022

NATCO gets CTPR launch approval from Delhi High Court

NATCO is the first company in India to have received its registration approval given by Central Insecticide Board & Registration Committee (CIB&RC) for indigenous manufacture of Chlorantraniliprole


Merck to initiate new Phase 3 clinical program for treatment of HIV-1 Infection
Clinical Trials | September 21, 2022

Merck to initiate new Phase 3 clinical program for treatment of HIV-1 Infection

Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir


Tezspire approved in the EU for the treatment of severe asthma
Drug Approval | September 21, 2022

Tezspire approved in the EU for the treatment of severe asthma

First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations


Quinten Health closes its financing round to advance disease modeling platforms
News | September 21, 2022

Quinten Health closes its financing round to advance disease modeling platforms

Quinten Health will announce in the coming months strategic partnerships with big pharma companies and data owners to launch the first disease modeling platforms.